Clinical research Objectives and methodology of Romanian SEPHAR II Survey. Project for comparing the prevalence and control of cardiovascular risk factors in two east-European countries: Romania and Poland

Abstract

IntroductionComparing results of representative surveys conducted in different East-European countries could contribute to a better understanding and management of cardiovascular risk factors, offering grounds for the development of health policies addressing the special needs of this high cardiovascular risk region of Europe. The aim of this paper was to describe the methodology on which the comparison between the Romanian survey SEPHAR II and the Polish survey NATPOL 2011 results is based.Material and methodsSEPHAR II, like NATPOL 2011, is a cross-sectional survey conducted on a representative sample of the adult Romanian population (18 to 80 years) and encompasses two visits with the following components: completing the study questionnaire, blood pressure and anthropometric measurements, and collection of blood and urine samples.ResultsFrom a total of 2223 subjects found at 2860 visited addresses, 2044 subjects gave written consent but only 1975 subjects had eligible data for the analysis, accounting for a response rate of 69.06%. Additionally we excluded 11 subjects who were 80 years of age (NATPOL 2011 included adult subjects up to 79 years). Therefore, the sample size included in the statistical analysis is 1964. It has similar age groups and gender structure as the Romanian population aged 18–79 years from the last census available at the moment of conducting the survey (weight adjustments for epidemiological analyses range from 0.48 to 8.7).ConclusionsSharing many similarities, the results of SEPHAR II and NATPOL 2011 surveys can be compared by a proper statistical method offering crucial information regarding cardiovascular risk factors in a high-cardiovascular risk European region.

Is statin-modified reduction in lipids the most important preventive therapy for cardiovascular disease? A pro/con debate

“…According to available studies residual risk involves 50–70 % of patients treated with statins, and recent data from the EUROASPIRE IV survey suggest that despite the fact that the majority (87 %) of secondary prevention patients now receive a statin, only 21 % of high-risk patients have LDL-C levels below 70 mg/dl (1.8 mmol/l) and 58 % below 100 mg/dl (2.5 mmol/l) [ 20 ]. Several factors can influence residual risk; this is associated with patients at very high risk with concomitant diseases and polypharmacy, and the problem of significant underuse of high doses of statins – in many European countries as well as in the United States atorvastatin 80 mg or rosuvastatin 40 mg is used in <5 % of dyslipidaemic patients [ 20 – 22 ]. Finally the question is whether we should expect that one drug (a statin) would completely reduce the overall risk?…”

Effect of Combined Use of Astragaloside IV (AsIV) and Atorvastatin (AV) on Expression of PPAR-γ and Inflammation-Associated Cytokines in Atherosclerosis Rats

“…As a chronic inflammatory disease, atherosclerosis is the main reason for the rising mortality worldwide. In the early stage, endothelial dysfunction is a critical event in atherosclerosis, which recruits macrophages into intima, leading to the further initiation of atherosclerosis [ 1 ]. Hence, elucidating the molecular mechanisms in the inflammatory process of early atherosclerosis is important in the development of novel intervention strategies for atherosclerosis.…”

Lipoprotein(a) is associated with left ventricular systolic dysfunction in a Chinese population of patients with hypertension and without coronary artery disease

“…Hypertension, alone or in combination with ischemic heart disease, precedes the development of heart failure and causes more deaths. The relative risk of CHF among patients with hypertension is significantly higher than in the general population [ 14 ]. Hypertension is one of the most important modifiable risk factors for CHF [ 15 ].…”